Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEVO-MEMS: Comparison of the haemodynamic profile of dobutamine and levosimendan
2022-002688-31Phase 4Active
- Sponsor
- Germans Trias i Pujol Research Institute
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of dobutamine and levosimendan in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Germans Trias i Pujol Research Institute. Primary endpoints: Pulmonary arterial pressure and Cardiac output. Started Aug 2022; status: active.
02
Drugs
dobutaminelevosimendan
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2022-002688-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002688-31.